Cancer Biomarkers Market by Biomarker Type (Genetic Biomarkers, Protein Biomarkers, and Other Biomarkers); by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Blood Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Stomach Cancer, and Other Cancer Types); by Profiling Technology (Imaging technologies, Omic Technologies (Proteomics, Genomics, and Other Omic Technologies), Cytogenetics-Based Tests, and Immunoassays); and for Application (Drug discovery and Development, Personalized medicine, Diagnostics, and Other Applications)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 - 2029

                                          
Abstract
                    
The report covers forecast and analysis for the cancer biomarkers market on a global and regional level. The study provides historic data of 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the cancer biomarkers market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the cancer biomarkers market on a global level.

In order to give the users of this report a comprehensive view of the cancer biomarkers market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein biomarker type segment, cancer type segment, , and profiling technology segment are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new cancer type launch, agreements, partnerships, collaborations & joint ventures, research & development, cancer type, and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, product portfolio of various companies according to region.

The study provides a decisive view of the cancer biomarkers market by segmenting the market based on biomarker type segment, cancer type, and profiling technology, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. Based on biomarker type the global cancer biomarkers market is segmented as genetic biomarkers, protein biomarkers, and other biomarkers. Based on cancer type, the market is segmented as breast cancer, colorectal cancer, lung cancer, prostate cancer, blood cancer, melanoma, ovarian cancer, liver cancer, stomach cancer, and other cancer types. By profiling technology, the cancer market is further segmented as imaging technologies, omic technologies, cytogenetics-based tests, and immunoassays. The omic technologies segment is further segmented as genomics, proteomics, and other omic technologies. Based on applications, the cancer biomarkers market segmented as drug discovery and development, personalized medicine, diagnostics, and other applications. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and the Middle East & Africa with its further bifurcation into major countries including the U.S., Rest of North America, U.K., Germany, France, Italy, Spain, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, Brazil, Rest of Latin America, GCC Countries, South Africa and Rest of Middle East and Africa. 

The report also includes detailed profiles of end players such as Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, QIAGEN, Illumina, Inc., QIAGEN, Sino Biological Inc., Merck & Co., Inc., Novartis AG, Hologic, Inc., bioMérieux SA, Genomic Health, Inc.

This report segments the global cancer biomarkers market as follows:

Global Cancer Biomarkers Market: Biomarker Type Segment Analysis

	Genetic Biomarkers 
	Protein Biomarkers 
	Other Cancer Biomarkers

Global Cancer Biomarkers Market: Cancer Type Segment Analysis

	Breast Cancer 
	Lung Cancer 
	Prostate Cancer 
	Colorectal Cancer 
	Blood Cancer
	Melanoma 
	Ovarian Cancer
	Liver Cancer
	Stomach Cancer
	Other Cancer Types 

Global Cancer Biomarkers Market: Profiling Technology Segment Analysis

	Imaging technologies
	Omic Technologies
	
		Proteomics
		Genomics
		Other Omic technologies
	
	
	Cytogenetics-Based Tests
	Immunoassays

Global Cancer Biomarkers Market: Applications  Segment Analysis

	Drug discovery and Development
	Personalized medicine
	Diagnostics
	Others

Global Cancer Biomarkers Market: Regional Segment Analysis

	North America
	
		The U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	Middle East and Africa